Trials / Completed
CompletedNCT01749514
Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)
A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effects of luspatercept (MK-6143, formerly called ACE-536) on anemia in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS). There is no primary hypothesis in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Luspatercept | Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days). |
Timeline
- Start date
- 2013-01-21
- Primary completion
- 2018-10-22
- Completion
- 2018-10-22
- First posted
- 2012-12-13
- Last updated
- 2024-07-29
- Results posted
- 2024-07-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01749514. Inclusion in this directory is not an endorsement.